KBC Group NV lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2,047.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV.

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...